Acepodia Inc.’s antibody cell conjugation platform could change the way CAR T-cell therapies are manufactured, clearing the way for an off-the-shelf model to treat numerous cancers that is safer and ...
Through Pfizer Ignite, Acepodia will gain access to Pfizer's resources, scale and expertise as the company broadens the application of its platform beyond oncology into autoimmune diseases Pfizer ...
Abclone announced on April 7 that the next-generation antibody-drug conjugate (ADC) technology, which it licensed from the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results